RemeGen Co. Ltd. A (688331)
Shanghai Stock Exchange · China · prices in CNY · close of 19 Oct 2026
Key indicators
| Last close | CNY 97.10 |
|---|---|
| 52-week range | 75.03 – 157.80 |
| Return, 1 month / 3 months | −14.9% / −28.2% |
| Return, 1 year / 3 years | −10.5% / +49.9% |
| Trend | Below its 200-day average |
| RSI (14) | 29 |
| Volatility (1 year) | 68.0% |
| Worst drawdown (1 year) | -36.6% |
| Average daily value traded | 862.35M CNY |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
RemeGen is a Chinese biopharmaceutical company based in Yantai that discovers, develops and commercialises biologic medicines. It focuses on antibody-drug conjugates and fusion proteins aimed at autoimmune diseases and cancer. Its products include a fusion protein for systemic lupus erythematosus and an antibody-drug conjugate for certain solid tumours. The company serves patients and healthcare providers in China and works with partners abroad to develop and market its therapies.
RemeGen Co. Ltd. A trades under the code 688331 on the Shanghai Stock Exchange in China, with its price quoted in Chinese yuan (CNY). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
RemeGen Co. Ltd. A (688331) trades on the Shanghai Stock Exchange in China. It last closed at CNY 97.10 on 19 October 2026.
Its price-based Market X-Ray is 52 out of 100 (a fair price profile), ranking 1,046 of 2,278 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 10.5% and over the last three months it fell 28.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Shanghai Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 58 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -16.0% | ||
| From 52-week high | -36.6% | ||
| Momentum | 34 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -28.2% | ||
| 6-month return | -28.3% | ||
| 12-month return, skipping the last month | 5.1% | ||
| Stability (higher is calmer) | 41 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 68.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -36.6% | ||
| Liquidity | 90 · Strong | Trades actively. | |
| Average daily value traded | 862.35M CNY | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −10.8% |
|---|---|
| 1 month | −14.9% |
| 3 months | −28.2% |
| 6 months | −28.3% |
| 1 year | −10.5% |
| 3 years | +49.9% |
| 5 years | – |
Signals
| 50-day / 200-day average | 119.22 / 115.61 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 5.62 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Shanghai Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.